Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison

CSL112 (apolipoprotein A‐I [apoA‐I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study aimed to compare the pharmacokinetics (PKs), pharmacodynamics (PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Bo, Goto, Shinya, Clementi, Regina, Feaster, John, Duffy, Danielle, Dalitz, Penelope, Airey, Jolanta, Korjian, Serge, Tortorici, Michael A., Roberts, John, Gibson, C. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579388/
https://www.ncbi.nlm.nih.gov/pubmed/35933730
http://dx.doi.org/10.1111/cts.13361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579388/
https://www.ncbi.nlm.nih.gov/pubmed/35933730
http://dx.doi.org/10.1111/cts.13361

Ejemplares similares